# **RAYMED LABS LIMITED**

CIN: L24111UP1992PLC014240 Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, Website- www.raymedlab.com E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 13.11.2021

The Head- Listing Compliance BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400001

#### Scrip Code: 531207

### Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, i.e. Saturday,  $13^{th}$  day of November, 2021 (commenced at <u>03:00 P.M.</u> and concluded at <u>03:50 P.M.</u>), has inter alia approved and passed the following resolutions:

- 1. The Unaudited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and half year ended September 30, 2021.(Copy enclosed)
- 2. Took note of the Limited Review Report as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter and half year ended September 30, 2021.(Copy enclosed)
- **3.** Took note of the **Cash Flow Statement** as per Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for quarter and half year ended September 30, 2021.(**Copy enclosed**)
- **4.** Took note of Statement of Investor Complaints/Grievances under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended September 30, 2021.
- **5.** Took note of Closure of Trading Window for Designated Persons as required under SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 for the quarter ended September 30, 2021.
- **6.** Took note of Certificate of Non Applicability of Compliance with Report on Corporate Governance as required under Regulation 27(2) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter ended September 30, 2021.
- **7.** Took note of The Reconciliation of Share Capital Audit Report Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2021.

# **RAYMED LABS LIMITED**

CIN: L24111UP1992PLC014240 Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, Website- www.raymedlab.com E-mail- <u>raymedlabs@rediffmail.com</u>, Phone no. - 0120-2426900, 9412700300

- 8. Took note of Shareholding pattern pursuant to Regulation 31 of the (Listing Obligations and Disclosure Requirements) Regulation 2015 for the quarter ended September 30, 2021.
- **9.** Took note of Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2021.

Kindly take the above information on your records.

Thanking you,

For Raymed Labs Limited

Ajai Goyal Whole Time Director DIN: 02636418

Place: Noida


# A.Kay Mehra & Co. CHARTERED ACCOUNTANTS

2470 (Basement), Hudson Line, GTB Nagar, Delhi-110009 Tel. No. : 011-42461274, 9891295255 E-mail : akmca1969@gmail.com Website : www.akmca.in

LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30<sup>TH</sup> SEPTEMBER,2021.

To The Board of Directors Raymed Labs Limited 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304

- We have reviewed the accompanying statement of unaudited financial results ("The Statement") of Raymed Labs Limited ("The Company") for the period ended on 30<sup>th</sup> September, 2021, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity Terssued by the Institute of



HEAD OFFICE : 120/128, LAJPAT NAGAR, KANPUR-208 005, PH. No. : 0512-2240909, 9956358976 BRANCH OFFICE : C-32, SECTOR-14, NOIDA-201301 Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. Kay. Mchra & Co. Chartered Accountants FRN-050004C

,ab

AccoDeepak Suneja (Partner)

(Membership NO- 501957)

Date: November 13, 2021 Place: Noida UDIN:- 21501957AAAANX9835

#### Raymed Labs Limited Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240 E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

<u>Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended September</u> <u>30, 2021</u>

Amt. (In Lacs)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.202 1
	(Unaudite d)	(Unaudite d)	(Unaudite d)	(Unaudite d)	(Unaudite d)	(Audited)
I. Revenue from Operations	0.00	0.00	0.00	0.00	0.00	0.00
II. Other Income	0.00	0.00	0.33	0.00	0.66	0.66
III. Total Income (I +II)	0.00	0.00	0.33	0.00	0.66	0.66
IV. Expenses						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
Purchases of Stock- in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.78	0.44	0.23	1.22	0.45	2.00
Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	0.13	0.13	0.14	0.26	0.29	0.57
Other Expenses	0.36	0.34	0.14	0.70	0.65	4.97
Total Expenses (IV)	1.27	0.91	0.51	2.18	1.39	7.54
V. Profit/(Loss) before exceptional items and tax (III- IV)	-1.27	-0.91	-0.18	-2.18	-0.73	-6.88
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	-1.27	-0.91	-0.18	-2.18	-0.73	-6.88
VIII. Tax Expense				0.00		
(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00	0.00

IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-1.27	-0.91	-0.18	-2.18	-0.73	-6.88
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00		0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-1.27	-0.91	-0.18	-2.18	-0.73	-6.88
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00		0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	-1.27	-0.91	-0.18	-2.18	-0.73	-6.88
XVI. Paid up Equity Share Capital (Face Value of Rs. 10/- Each)	427.35	427.35	427.35	427.35	427.35	427.35
XVII. Other Equity	0.00	0.00	0.00	0.00	0.00	-632.64
XIX. Earnings per equity share (for continuing	0.00	0.00	0.00	0.00	0.00	0.00

operation):						
(1) Basic	-0.0297	-0.0214	-0.0041	-0.0511	-0.0171	-0.1611
(2) Diluted	-0.0297	-0.0214	-0.0041	-0.0511	-0.0171	-0.1611
XX. Earnings per equity share (for discontinued operation):	0.000	0.000	0.000	0.000	0.000	0.000
(1) Basic	0.000	0.000	0.000	0.00	0.00	0.00
(2) Diluted	0.000	0.000	0.000	0.00	0.00	0.00
XXI. Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	-0.0297	-0.0214	-0.0041	-0.0511	-0.0171	-0.1611
(2) Diluted	-0.0297	-0.0214	-0.0041	-0.0511	-0.0171	-0.1611

#### Notes:

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 13<sup>th</sup> November 2021. The Statutory Auditors have conducted a limited review of the above unaudited financial results and have expressed an unmodified report on the same.

(2) The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

(3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

(4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.

(5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

For on behalf of Raymed Labs Limited

Ajai Goyal Director DIN : 02636418 Date: 13.11.2021 Place : Noida

#### Raymed Labs Limited Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240 E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

Amount in Lakh			
Particulars	As at Current Half Year Ended	As at Previous Year Ended	
	30.09.2021	31.03.2021	
	(Unaudited)	(Audited)	
ASSETS			
Non current assets			
(a) Property, Plant and Equipment	15.83	16.09	
(b) Capital Work in Progress	0.00	0.00	
(c) Investment Property	0.00	0.00	
(d) Goodwill	0.00	0.00	
(e) Other Intangible Assets	0.03	0.03	
(f) Intengible assets under development	0.00	0.00	
(g) Biological Assets other than bearer plants	0.00	0.00	
(h) Financials Assets-	0.00	0.00	
(i) Investments	0.00	0.00	
(ii) Trade Receivables		0.00	
(iii) Loans	0.00	0.00	
(iv) Other(to be specified)	0.00	0.00	
(i) Deferred tax assets (net)	0.00	0.00	
(j) Other non-current assets	0.00	0.00	
Current Assets			
(a) Inventories	0.00	0.00	
(b) Financials Assets	0.00	0.00	
(i) Investments	0.00	0.00	
(ii) Trade receivables	2.49	2.49	
(iii) Cash and cash equivalents	0.05	0.15	
(iv) Bank Balance other than (iii) above	0.03	0.03	
(v) Loans			
(vi) Otheres (to be specified)	6.10	6.10	
(c) Current tex Assets	0.00	0.00	
(d) Other current Assets	0.00	0.00	
TOTAL ASSETS	0.28	0.28	
	24.81	25.16	

Statement of Audited Standalone/Consolidated Assets and Liabilities

EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	-634.82	-632.64
Liabliaties		
Non -Current liabilites		
(a) Financials Liablities		
(i) Borrowings	0.00	0.00
(ii) Trade Payable	0.00	0.00
(iii) Other Financial liablities (other than specified in item (b) to be specified	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deffered Tax Liabilites (net)	0.00	0.00
(d) Other Non-Current Liablities	0.00	0.00
Current Liablities		
(a) Financials Liablities		
(i) Borrowings	217.55	216.33
(ii) Trade Payables	6.21	5.60
(iii) Other Financial liablities (other than specified in item (c) tobe specified	5.00	5.00
(b) Other current liabilities	0.28	0.28
(c) provisions	3.24	3.24
(d) Current Tax Liablitries	0.00	0.00
TOTAL EQUITY AND LIABILITES	24.81	25.16

For on behalf of Raymed Labs Limited

Ajai Goyal Director DIN : 02636418

Date: 13.11.2021 Place : Noida

#### Raymed Labs Limited Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240 E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

#### UNAUDITED STANDALONE &/OR CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2021

Particulars	Six Months ended September 30, 2021 (01.04.2021 to 30.09.2021) (Unaudited)
Cash flow from Operating Activities	
Profit Before Tax	-2.18
Adjustments for	
Adjustments for finance costs	
Adjustments for decrease (increase) in inventories	
Adjustments for decrease (increase) in trade receivables, current	
Adjustments for decrease (increase) in trade receivables, non-current	
Adjustments for decrease (increase) in other current assets	
Adjustments for other financial assets, non-current	
Adjustments for other financial assets, current	
Adjustments for other bank balances	
Adjustments for increase (decrease) in trade payables, current	
Adjustments for increase (decrease) in trade payables, non-current	
Adjustments for increase (decrease) in other current liabilities	0.61
Adjustments for increase (decrease) in other non-current liabilities	
Adjustments for depreciation and amortisation expense	0.26
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	
Adjustments for provisions, current	
Adjustments for provisions, non-current	
Adjustments for other financial liabilities, current	1.22
Adjustments for other financial liabilities, non-current	
Adjustments for unrealised foreign exchange losses gains	
Adjustments for dividend income	
Adjustments for interest income	
Adjustments for share-based payments	
Adjustments for fair value losses (gains)	
Adjustments for undistributed profits of associates	
Other adjustments for which cash effects are investing or financing cash flow	
Other adjustments to reconcile profit (loss)	
Other adjustments for non-cash items	

Share of profit and loss from partnership firm or association of persons or limited	
liability partnerships	
Total adjustments for reconcile profit (loss)	2.09
Net cash flows from (used in) operations	-0.10
Dividends received	
Interest paid	
Interest received	
Income taxes paid (refund)	
Other inflows (outflows) of cash	
Net cash flows from (used in) operating activities	-0.10
Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	
Cash flows used in obtaining control of subsidiaries or other businesses	
Other cash receipts from sales of equity or debt instruments of other entities	
Other cash payments to acquire equity or debt instruments of other entities	
Other cash receipts from sales of interests in joint ventures	
Other cash payments to acquire interests in joint ventures	
Cash receipts from share of profits of partnership firm or association of persons or	
limited liability partnerships	
Cash payment for investment in partnership firm or association of persons or	
limited	
liability partnerships	
Proceeds from sales of property, plant and equipment	
Purchase of property, plant and equipment	
Proceeds from sales of investment property	
Purchase of investment property	
Proceeds from sales of intangible assets	
Purchase of intangible assets	
Proceeds from sales of intangible assets under development	
Purchase of intangible assets under development	
Proceeds from sales of goodwill	
Purchase of goodwill	
Proceeds from biological assets other than bearer plants	
Purchase of biological assets other than bearer plants	
Proceeds from government grants	
Proceeds from sales of other long-term assets	
Cash receipts from repayment of advances and loans made to other parties	
Cash payments for future contracts, forward contracts, option contracts and swap contracts	
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	
Dividends received	
Interest received	
Income taxes paid (refund)	

Other inflows (outflows) of cash	
Net cash flows from (used in) investing activities	
Cash flows from used in financing activities	
Proceeds from changes in ownership interests in subsidiaries	
Payments from changes in ownership interests in subsidiaries	
Proceeds from issuing shares	
Proceeds from issuing other equity instruments	
Payments to acquire or redeem entity's shares	
Payments of other equity instruments	
Proceeds from exercise of stock options	
Proceeds from issuing debentures notes bonds etc	
Proceeds from borrowings	
Repayments of borrowings	
Payments of finance lease liabilities	
Payments of lease liabilities	
Dividends paid	
Interest Paid	
Income taxes paid (refund)	
Other inflows (outflows) of cash	
Net cash flows from (used in) financing activities	
Net increase (decrease) in cash and cash equivalents before effect of exchange	-0.10
rate	
changes	
Effect of exchange rate changes on cash and cash equivalents	0.00
Effect of exchange rate changes on cash and cash equivalents	0.00
Net increase (decrease) in cash and cash equivalents	-0.10
Cash and cash equivalents cash flow statement at beginning of period	0.15
Cash and cash equivalents cash flow statement at end of period	0.05

**Notes** : The above results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 13.11.2021. The Statutory auditors have conducted a limited review of the above unaudited financial results and have expressed an unmodified report on the same.

#### For or on behalf of Raymed Labs Limited

Ajai Goyal Director DIN: 02636418

Date: 13.11.2021 Place: Noida

## **RAYMED LABS LIMITED**

CIN: L24111UP1992PLC014240 Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, Website- www.raymedlab.com E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 13.11.2021

The Head- Listing Compliance BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400001

Scrip Code: 531207

#### <u>Subject: Non Applicability of Compliance with Statement of Deviation(s) or Variation(s) as</u> per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter and half year ended September 30, 2021

Dear Sir/Madam,

With reference to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the disclosure of Statement of Deviation(s) or Variation(s) under the said regulation is not applicable to the Company.

Kindly take the same in your records.

Thanking You,

Yours Sincerely,

For Raymed Labs Limited

Ajai Goyal Whole Time Director DIN: 02636418

Place: Noida